Non-small cell lung carcinoma (NSCLC)
IOVAIovance BiotherapeuticsCatalyst overview
Research summary
This catalyst tracks a Phase 2 data readout for Iovance TIL (LN-145) in Non-small cell lung carcinoma (NSCLC). The expected timing is based on the latest available company guidance and may change.
IOV-LUN-202 trial. 12/27/23- Placed on clinical hold on 12/22/23. 3/4/24- Clinical hold lifted. 11/3/25- Interim data reported. Present add'l data at upcoming medical meeting in 2026. 11/06/25:- Interim data show 26% ORR, mDOR not reached; enrollment complete 2026; updated data 2026; sBLA, launch 2027. 02/24/26:- FDA Fast Track in 2L NSQ NSCLC; updated data, enrollment, sBLA, launch timelines reiterated for 2026-2H27. 05/07/26:- IOV-LUN-202 milestones reiterated: 2026 data update and enrollment completion; potential accelerated US approval and 2H 2027 launch. 08/06/26:- IOV-LUN-202 enrollment nearly complete; program updates expected Q4 2026; sBLA planned 2027.
Verification
Confirm timing and program details against the company announcement or filing.